Successful Treatment of SARS-CoV-2 Vaccination-related Activation of Rheumatoid Arthritis with Positive Findings for Epstein-Barr Virus

Overview

Journal Intern Med

Specialty General Medicine

Date 2022 Apr 25

PMID 35466171

Authors

Hideki Nakamura

Yosuke Nagasawa

Hitomi Kobayashi

Masako Tsukamoto

Tadateru Takayama

Noboru Kitamura

Affiliations

Soon will be listed here.

Abstract

We herein report a 60-year-old woman who experienced severe flare of rheumatoid arthritis (RA) and Epstein-Barr virus (EBV) positivity following administration of the messenger ribonucleic acid (mRNA)-type severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. Since 40 years old, she had been in long-term remission of anti-citrullinated protein antibody-positive RA. Ten days after SARS-CoV-2 vaccination, she presented with a high fever and polyarthritis, active synovitis on joint ultrasound, a clinical disease activity index of 35, and positivity for anti-early antigen, diffuse type and restricted type (EA DR) IgG and EBV deoxyribonucleic acid (EBV-DNA). Tocilizumab was introduced to treat RA. The RA disease activity disappeared, and anti-EA DR IgG and EBV-DNA became negative.

References

Stevens E, Weinblatt M, Massarotti E, Griffin F, Emani S, Desai S . Safety of the Zoster Vaccine Recombinant Adjuvanted in Rheumatoid Arthritis and Other Systemic Rheumatic Disease Patients: A Single Center's Experience With 400 Patients. ACR Open Rheumatol. 2020; 2(6):357-361. PMC: 7301873. DOI: 10.1002/acr2.11150. View

Chiu Y, Chen D . Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics. Expert Rev Clin Immunol. 2019; 16(2):207-228. DOI: 10.1080/1744666X.2019.1705785. View

Hasseli R, Mueller-Ladner U, Hoyer B, Krause A, Lorenz H, Pfeil A . Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. RMD Open. 2021; 7(1). PMC: 7823432. DOI: 10.1136/rmdopen-2020-001464. View

Kato A, Matsuo S, Takai H, Uchiyama Y, Mihara M, Suzuki M . Early effects of tocilizumab on bone and bone marrow lesions in a collagen-induced arthritis monkey model. Exp Mol Pathol. 2008; 84(3):262-70. DOI: 10.1016/j.yexmp.2008.03.003. View

van der Linden M, Knevel R, Huizinga T, van der Helm-van Mil A . Classification of rheumatoid arthritis: comparison of the 1987 American College of Rheumatology criteria and the 2010 American College of Rheumatology/European League Against Rheumatism criteria. Arthritis Rheum. 2010; 63(1):37-42. DOI: 10.1002/art.30100. View

Chevassut T, Hunt B, Pavord S . VITT, COVID-19 and the Expert Haematology Panel: The story of how the UK responded to emerging cases of vaccine-induced immune thrombocytopenia and thrombosis during the vaccination programme. Clin Med (Lond). 2021; 21(6):e600-e602. PMC: 8806298. DOI: 10.7861/clinmed.2021-0488. View

Levin D, Shimon G, Fadlon-Derai M, Gershovitz L, Shovali A, Sebbag A . Myocarditis following COVID-19 vaccination - A case series. Vaccine. 2021; 39(42):6195-6200. PMC: 8416687. DOI: 10.1016/j.vaccine.2021.09.004. View

Winthrop K, Tanaka Y, Lee E, Wollenhaupt J, Al Enizi A, Azevedo V . Prevention and management of herpes zoster in patients with rheumatoid arthritis and psoriatic arthritis: a clinical review. Clin Exp Rheumatol. 2021; 40(1):162-172. DOI: 10.55563/clinexprheumatol/cpu6r9. View

Kitamura N, Sugiyama K, Nagasawa Y, Hamaguchi M, Kobayashi H, Takei M . Involvement of Epstein-Barr virus in the development and spontaneous regression of methotrexate-associated lymphoproliferative disorder in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2021; 40(7):1330-1335. DOI: 10.55563/clinexprheumatol/lgfbtq. View

10.

Gold J, Okyay R, Licht W, Hurley D . Investigation of Long COVID Prevalence and Its Relationship to Epstein-Barr Virus Reactivation. Pathogens. 2021; 10(6). PMC: 8233978. DOI: 10.3390/pathogens10060763. View

11.

Li P, Zhang X, Cao W, Yang F, Du X, Shi Z . RIG-I is responsible for activation of type I interferon pathway in Seneca Valley virus-infected porcine cells to suppress viral replication. Virol J. 2018; 15(1):162. PMC: 6199795. DOI: 10.1186/s12985-018-1080-x. View

12.

Yamamoto S, Nishimura K, Yo K, Waki D, Murabe H, Yokota T . Flare-up of adult-onset Still's disease after receiving a second dose of BNT162b2 COVID-19 mRNA vaccine. Clin Exp Rheumatol. 2021; 39 Suppl 132(5):139-140. DOI: 10.55563/clinexprheumatol/tvlpnc. View

13.

Endo Y, Fukui S, Koga T, Sasaki D, Hasegawa H, Yanagihara K . Tocilizumab has no direct effect on cell lines infected with human T-cell leukemia virus type 1. J Int Med Res. 2021; 49(3):3000605211002083. PMC: 7989142. DOI: 10.1177/03000605211002083. View

14.

Wilting F, Kotsopoulos A, Platteel A, van Oers J . Intracerebral Hemorrhage and Thrombocytopenia After AstraZeneca COVID-19 Vaccine: Clinical and Diagnostic Challenges of Vaccine-Induced Thrombotic Thrombocytopenia. Cureus. 2021; 13(9):e17637. PMC: 8486363. DOI: 10.7759/cureus.17637. View

15.

Patel V, Pulungan Z, Shah A, Kambhampati M, Lobo F, Petrilla A . Risk and cost of infection-related hospitalizations in medicare beneficiaries with comorbid rheumatoid arthritis treated with abatacept versus other targeted disease-modifying anti-rheumatic drugs. J Med Econ. 2021; 24(1):299-307. DOI: 10.1080/13696998.2021.1881525. View

16.

Fukui S, Nakamura H, Takahashi Y, Iwamoto N, Hasegawa H, Yanagihara K . Tumor necrosis factor alpha inhibitors have no effect on a human T-lymphotropic virus type-I (HTLV-I)-infected cell line from patients with HTLV-I-associated myelopathy. BMC Immunol. 2017; 18(1):7. PMC: 5292003. DOI: 10.1186/s12865-017-0191-2. View

17.

Yamakawa N, Fujimoto M, Kawabata D, Terao C, Nishikori M, Nakashima R . A clinical, pathological, and genetic characterization of methotrexate-associated lymphoproliferative disorders. J Rheumatol. 2013; 41(2):293-9. DOI: 10.3899/jrheum.130270. View

18.

Biehl A, Harinstein L, Brinker A, Glaser R, Munoz M, Avigan M . A case series analysis of serious exacerbations of viral hepatitis and non-viral hepatic injuries in tocilizumab-treated patients. Liver Int. 2020; 41(3):515-528. DOI: 10.1111/liv.14766. View

19.

Conaghan P, Peterfy C, Olech E, Kaine J, Ridley D, DiCarlo J . The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy. Ann Rheum Dis. 2014; 73(5):810-6. PMC: 3995246. DOI: 10.1136/annrheumdis-2013-204762. View

20.

Esquivel-Valerio J, Skinner-Taylor C, Moreno-Arquieta I, Cardenas-de la Garza J, Garcia-Arellano G, Gonzalez-Garcia P . Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study. Rheumatol Int. 2021; 41(12):2105-2108. PMC: 8496432. DOI: 10.1007/s00296-021-05017-9. View